4 hours ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Rating of “Buy” from Brokerages MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has been assigned an average rating of “Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a buy recomme…
Nasdaq 100 · Pharmaceuticals · Science